bluebird bio, Inc. (NASDAQ:BLUE) Shares Sold by Wells Fargo & Company MN

Wells Fargo & Company MN cut its holdings in bluebird bio, Inc. (NASDAQ:BLUE) by 93.8% during the fourth quarter, HoldingsChannel reports. The firm owned 6,261 shares of the biotechnology company’s stock after selling 95,494 shares during the period. Wells Fargo & Company MN’s holdings in bluebird bio were worth $52,000 as of its most recent filing with the SEC.

Separately, Regeneron Pharmaceuticals Inc. acquired a new position in bluebird bio in the fourth quarter valued at $175,000. 87.43% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

BLUE has been the topic of a number of recent research reports. StockNews.com initiated coverage on shares of bluebird bio in a research note on Wednesday, May 7th. They issued a “sell” rating on the stock. Wells Fargo & Company dropped their price target on shares of bluebird bio from $40.00 to $5.00 and set an “equal weight” rating on the stock in a research note on Monday, February 24th. Baird R W lowered shares of bluebird bio from a “strong-buy” rating to a “hold” rating in a research note on Friday, February 21st. JPMorgan Chase & Co. upgraded shares of bluebird bio from an “underweight” rating to a “neutral” rating in a research note on Monday, February 24th. Finally, Barclays dropped their price target on shares of bluebird bio from $40.00 to $8.00 and set an “overweight” rating on the stock in a research note on Monday, March 31st. One research analyst has rated the stock with a sell rating, six have issued a hold rating and two have given a buy rating to the company. According to MarketBeat.com, the company has an average rating of “Hold” and an average price target of $44.60.

bluebird bio Stock Up 0.6%

BLUE stock opened at $3.31 on Wednesday. The company has a market cap of $32.40 million, a P/E ratio of -0.09 and a beta of 0.27. bluebird bio, Inc. has a 52 week low of $3.20 and a 52 week high of $28.60. The company’s 50-day moving average price is $4.20 and its 200 day moving average price is $6.41. The company has a current ratio of 0.51, a quick ratio of 0.33 and a debt-to-equity ratio of 0.37.

About bluebird bio

bluebird bio, Inc, a biotechnology company, researches, develops, and commercializes gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include ZYNTEGLO (betibeglogene autotemcel) for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell disease (SCD); and SKYSONA (elivaldogene autotemcel) to treat cerebral adrenoleukodystrophy.